Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23735-23747

  Liu, Kaiyu ^a   Liu, Xujie ^b   Peng, Zhiping ^b   Sun, Haojie ^a,c   Zhang, Mingzhi ^a,c   Zhang, Jianning ^d   Liu, Shuang ^d   Hao, Limin ^e   Lu, Guoqiu ^e   Zheng, Kangcheng ^e   Gong, Xikui ^e   Wu, Di ^e   Wang, Fan ^a,c   Shen, Li ^a,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

^d NAVY GENERAL HOSPITAL   (China)

^e Beijing Scilight Biotechnology Ltd Co   (China)

Author keywords

Adoptive immunotherapy; Avidin CAR; Biotinylated; EGFRvIII; Optical imaging

Indexed keywords

AVIDIN; BIOTIN; CHIMERIC ANTIGEN RECEPTOR; DYE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLUORESCENCE IMAGING; GLIOMA; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BRAIN NEOPLASMS; DRUG SCREENING; GENETICS; IMMUNOLOGY; NUDE MOUSE; PATHOLOGY; PROCEDURES; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; AVIDIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYTOKINES; FEMALE; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MICE, NUDE; OPTICAL IMAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943398830     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4362     Document Type: Article

References (34)

1. Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S and Shibuya M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Molecular and cellular biology. 1988;8:1816-1820.
2. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS and Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America. 1992;89:2965-2969.
3. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK and Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:7727-7731.
4. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS and Cavenee WK. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. The Journal of biological chemistry. 1997;272:2927-2935.
5. Tang CK, Gong XQ, Moscatello DK, Wong AJ and Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer research. 2000;60:3081-3087.
6. Lammering G, Hewit TH, Valerie K, Contessa JN, Amorino GP, Dent P and Schmidt-Ullrich RK. EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene. 2003;22:5545-5553.
7. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y and Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer research. 2003;63:6962-6970.
8. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD and Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clinical cancer research :an official journal of the American Association for Cancer Research. 2004;10:3216-3224.
9. Liu X, Liu K, Qin J, Hao L, Li X, Liu Y, Zhang X, Liu X, Li P, Han S, Mao Z and Shen L. C/EBPbeta promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma. International journal of cancer Journal international du cancer. 2015;136:2524-2534.
10. Jutten B, Dubois L, Li Y, Aerts H, Wouters BG, Lambin P, Theys J and Lammering G. Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2009;92:393-398.
11. Jiang H, Wang H, Tan Z, Hu S, Wang H, Shi B, Yang L, Li P, Gu J, Wang H and Li Z. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. The Journal of biological chemistry. 2011; 286:5913-5920.
12. Gan HK, Burgess AW, Clayton AH and Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer research. 2012;72:2924-2930.
13. Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, 2nd, McLendon RE and Bigner DD. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nuclear medicine and biology. 2012;39:23-34.
14. Porter DL, Levine BL, Kalos M, Bagg A and June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England journal of medicine. 2011;365:725-733.
15. Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R and Gilham DE. Chimeric antigen receptors for T-cell based therapy. Methods in molecular biology (Clifton, NJ). 2012; 907:645-666.
16. Sadelain M, Brentjens R and Riviere I. The basic principles of chimeric antigen receptor design. Cancer discovery. 2013;3:388-398.
17. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA and Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of immunology (Baltimore, Md :1950). 2009;183:5563-5574.
18. Hombach AA and Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. International journal of cancer Journal international du cancer. 2011;129:2935-2944.
19. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK and Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. The Journal of clinical investigation. 2011;121:1822-1826.
20. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N and Powell DJ, Jr. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer research. 2012;72:1844-1852.
21. Urbanska K and Powell DJ. Development of a novel universal immune receptor for antigen targeting:To Infinity and beyond. Oncoimmunology. 2012;1:777-779.
22. Lim KH, Huang H, Pralle A and Park S. Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. Biotechnology and bioengineering. 2013; 110:57-67.
23. Lu PH and Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. Journal of immunology (Baltimore, Md :1950). 1994;153:1687-1696.
24. Baecher-Allan C, Viglietta V and Hafler DA. Human CD4+CD25+ regulatory T cells. Seminars in immunology. 2004;16:89-98.
25. Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL and Jensen MC. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. The journal of gene medicine. 2004;6:704-711.
26. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, et al. Antitumor activity and long-term fate of chimeric antigen receptorpositive T cells in patients with neuroblastoma. Blood. 2011;118:6050-6056.
27. Kandalaft LE, Powell DJ, Jr. and Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of translational medicine. 2012;10:157.
28. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA and Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Human gene therapy. 2012;23:1043-1053.
29. Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, Wang LL and Han WD. Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia. Molecular therapy :the journal of the American Society of Gene Therapy. 2015;23:184-191.
30. Liu XJ, Wu WT, Wu WH, Yin F, Ma SH, Qin JZ, Liu XX, Liu YN, Zhang XY, Li P, Han S, Liu KY, Zhang JM, He QH and Shen L. A minority subpopulation of CD133(+)/EGFRvIII(+)/EGFR(-) cells acquires stemness and contributes to gefitinib resistance. CNS neuroscience & therapeutics. 2013;19:494-502.
31. Klebanoff CA, Yamamoto TN and Restifo NP. Immunotherapy:Treatment of aggressive lymphomas with anti-CD19 CAR T cells. Nature reviews Clinical oncology. 2014;11:685-686.
32. Sautto GA, Wisskirchen K, Clementi N, Castelli M, Diotti RA, Graf J, Clementi M, Burioni R, Protzer U and Mancini N. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut. 2015.
33. Zhong XS, Matsushita M, Plotkin J, Riviere I and Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Molecular therapy :the journal of the American Society of Gene Therapy. 2010;18:413-420.
34. Lipowska-Bhalla G, Gilham DE, Hawkins RE and Rothwell DG. Targeted immunotherapy of cancer with CAR T cells:achievements and challenges. Cancer immunology, immunotherapy :CII. 2012;61:953-962.